<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Malar J</journal-id>
<journal-id journal-id-type="iso-abbrev">Malar. J</journal-id>
<journal-title-group>
<journal-title>Malaria Journal</journal-title>
</journal-title-group>
<issn pub-type="epub">1475-2875</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28558712</article-id>
<article-id pub-id-type="pmc">5450361</article-id>
<article-id pub-id-type="publisher-id">1877</article-id>
<article-id pub-id-type="doi">10.1186/s12936-017-1877-x</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular and immunological analyses of confirmed <italic>Plasmodium vivax</italic> relapse episodes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Maneerattanasak</surname>
<given-names>Sarunya</given-names>
</name>
<address>
<email>sarunya.man@student.mahidol.ac.th</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gosi</surname>
<given-names>Panita</given-names>
</name>
<address>
<email>panitag@afrims.org</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krudsood</surname>
<given-names>Srivicha</given-names>
</name>
<address>
<email>srivicha.kru@mahidol.ac.th</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chimma</surname>
<given-names>Pattamawan</given-names>
</name>
<address>
<email>pattamawan.chi@mahidol.ac.th</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tongshoob</surname>
<given-names>Jarinee</given-names>
</name>
<address>
<email>jarinee.pan@mahidol.ac.th</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mahakunkijcharoen</surname>
<given-names>Yuvadee</given-names>
</name>
<address>
<email>yuvadee.mah@mahidol.ac.th</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sukasem</surname>
<given-names>Chonlaphat</given-names>
</name>
<address>
<email>chonlaphat.suk@mahidol.ac.th</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Imwong</surname>
<given-names>Mallika</given-names>
</name>
<address>
<email>mallika.imw@mahidol.ac.th</email>
</address>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Snounou</surname>
<given-names>Georges</given-names>
</name>
<address>
<email>georges.snounou@upmc.fr</email>
</address>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Khusmith</surname>
<given-names>Srisin</given-names>
</name>
<address>
<phone>66-2-3549100-13</phone>
<email>srisin.khu@mahidol.ac.th</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution>Department of Microbiology and Immunology, </institution><institution>Faculty of Tropical Medicine, Mahidol University, </institution></institution-wrap>420/6 Rajvithi Road, Bangkok, 10400 Thailand </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0419 1772</institution-id><institution-id institution-id-type="GRID">grid.413910.e</institution-id><institution>Department of Immunology and Medicine, </institution><institution>Armed Forces Research Institute of Medical Science-United States Army Military Component, </institution></institution-wrap>Bangkok, Thailand </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution>Clinical Malaria Research Unit, </institution><institution>Faculty of Tropical Medicine, Mahidol University, </institution></institution-wrap>Bangkok, Thailand </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.416009.a</institution-id><institution>Office for Research and Development, </institution><institution>Faculty of Medicine Siriraj Hospital, Mahidol University, </institution></institution-wrap>Bangkok, 10700 Thailand </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution>Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, </institution><institution>Faculty of Medicine Ramathibodi Hospital, Mahidol University, </institution></institution-wrap>Bangkok, 10400 Thailand </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 4689 6957</institution-id><institution-id institution-id-type="GRID">grid.415643.1</institution-id><institution>Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), </institution><institution>Ramathibodi Hospital, </institution></institution-wrap>Bangkok, Thailand </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution>Department of Molecular Tropical Medicine and Genetics, </institution><institution>Faculty of Tropical Medicine, Mahidol University, </institution></institution-wrap>Bangkok, 10400 Thailand </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2308 1657</institution-id><institution-id institution-id-type="GRID">grid.462844.8</institution-id><institution>UPMC Univ Paris 06, Inserm (Institut National de la Santé et de la Recherche Medicale), Centre d’Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, ERL CNRS 8255 (Centre National de la Recherche Scientifique), </institution><institution>Sorbonne Universités, </institution></institution-wrap>91 Boulevard de l’Hôpital, 75013 Paris, France </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution>Center for Emerging and Neglected Infectious Diseases, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, Thailand </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>30</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>30</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>16</volume>
<elocation-id>228</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>3</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>5</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p>Relapse infections resulting from the activation hypnozoites produced by <italic>Plasmodium vivax</italic> and <italic>Plasmodium ovale</italic> represent an important obstacle to the successful control of these species. A single licensed drug, primaquine is available to eliminate these liver dormant forms. To date, investigations of vivax relapse infections have been few in number.</p>
</sec>
<sec>
<title>Results</title>
<p>Genotyping, based on polymorphic regions of two genes (<italic>Pvmsp1</italic>F3 and <italic>Pvcsp</italic>) and four microsatellite markers (MS3.27, MS3.502, MS6 and MS8), of 12 paired admission and relapse samples from <italic>P. vivax</italic>-infected patients were treated with primaquine, revealed that in eight of the parasite populations in the admission and relapse samples were homologous, and heterologous in the remaining four patients. The patients’ CYP2D6 genotypes did not suggest that any were poor metabolisers of primaquine. Parasitaemia tended to be higher in the heterologous as compared to the homologous relapse episodes as was the IgG3 response. For the twelve pro- and anti-inflammatory cytokine levels measured for all samples, only those of IL-6 and IL-10 tended to be higher in patients with heterologous as compared to homologous relapses in both admission and relapse episodes.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>The data from this limited number of patients with confirmed relapse episodes mirror previous observations of a significant proportion of heterologous parasites in relapses of <italic>P. vivax</italic> infections in Thailand. Failure of the primaquine treatment that the patients received is unlikely to be due to poor drug metabolism, and could indicate the presence of <italic>P. vivax</italic> populations in Thailand with poor susceptibility to 8-aminoquinolines.</p>
</sec>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (doi:10.1186/s12936-017-1877-x) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Antibodies</kwd>
<kwd>Cytokines</kwd>
<kwd>Genotyping</kwd>
<kwd>Relapse</kwd>
<kwd>
<italic>Plasmodium vivax</italic>
</kwd>
<kwd>Thailand</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>1.Royal Golden Jubilee Ph.D. Program (RGJ Program) of the Thailand Research Fund </institution>
</funding-source>
<award-id>PHD/0095/2554</award-id>
<principal-award-recipient>
<name>
<surname>Khusmith</surname>
<given-names>Srisin</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group>
<funding-source>
<institution>2.Office of Higher Education Commission, Ministry of Education, Thailand, Mahidol University under the National Research Universities Initiative</institution>
</funding-source>
</award-group>
<award-group>
<funding-source>
<institution>3.Faculty of Tropical Medicine, Mahidol University</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p>The origin of renewed parasitaemia following a primary infection by <italic>Plasmodium vivax</italic> or <italic>Plasmodium ovale</italic> treated with a schizontocidal drug is either a recrudescence due to erythrocytic parasites that have survived treatment, a re-infection, or a relapse consequent to merozoites released from a dormant liver stage, the hypnozoite, that has activated to resume normal development. Hypnozoites, which are not detectable, significantly extend the duration of the infection and the parasite’s potential to transmit, as a single infected mosquito bite can lead to multiple relapse episodes over many years. Relapse patterns vary between the parasite from temperate and tropical origin, and the risk for multiple relapse is highest in the tropics (50–80%) and lowest in temperate regions (5–10%) [<xref ref-type="bibr" rid="CR1">1</xref>]. In Southeast Asia, vivax infections are predicted to have a high relapse incidence rate (836 relapses per 100,000 person days) and a relatively rapid mean time from primary episode to first relapse (41 days) [<xref ref-type="bibr" rid="CR2">2</xref>]. The mechanisms behind the activation of hypnozoites and the determination of their periodicity remain unclear. Hypnozoites can only be eliminated by 8-aminoquinolines of primaquine which is safely administered only to persons without glucose-6-phosphate dehydrogenase deficiency. Thus, relapses are a major concern for efforts to control and eliminate vivax malaria [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
<p>It was assumed that the parasite populations emerging during relapses would be identical to those present during the primary episode, a notion that received support from early molecular studies [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. However, later investigations based more detailed genotyping analyses on relapses in diverse geographic regions revealed that the parasites in primary and relapse episodes are often genetically distinct, a phenomenon termed heterologous hypnozoite activation [<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. Thus, interpretation of drug efficacy studies against <italic>P. vivax</italic> in endemic countries cannot be corrected by genotyping analyses, as these will not allow distinguishing between a re-infection, a recrudescence, or a heterologous relapse.</p>
<p>The relapse pattern comprising the latency period and the number of relapse episodes is probably influenced by the level of immunity that the patients may have acquired during the primary attack [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. A degree of immunity is generally acquired following the primary infection, and experimental vivax infections clearly show that protection is strain-specific [<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>]. However, although the number of investigations on the immune responses in <italic>P. vivax</italic> is increasing, very few studies have addressed this in the context of relapse episodes [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR16">16</xref>].</p>
<p>In Thailand patients diagnosed with <italic>P. vivax</italic> receive a standard treatment of chloroquine and primaquine, though approximately 7% relapse within 6 months [<xref ref-type="bibr" rid="CR17">17</xref>]. Patients who present with <italic>P. vivax</italic> in Bangkok following a trip to endemic areas cannot be re-infected while they remain there, as malaria transmission does not occur in this city. This afforded the opportunity to recruit a cohort of vivax patients and to identify those with true relapse episodes during extended follow-up. In this manner a set 12 paired admission/relapse blood samples were obtained, and these were used to compare the genotypes of the parasites and a set of immune response markers.</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<sec id="Sec3">
<title>Samples</title>
<p>The stored packed red blood cells and plasma samples were obtained from Clinical Malaria Research Unit, Faculty of Tropical Medicine at Mahidol University (Bangkok, Thailand). The samples were collected between February 2012 and May 2013 prior to treatment by the Clinical Malaria Research Unit (Faculty of Tropical Medicine) from 12 patients (P1 to P12) on initial admission with <italic>P. vivax</italic> and when presenting with renewed clinical symptoms during follow-up. These infections were acquired while visiting malaria endemic areas along the Thai-Myanmar border in the west (P1, P2, P3, P4, P5, P6, P7, P9), the Thai–Cambodian border in the east (P10, P11), and the Thai-Lao border in the north (P8, P12). All patients were treated the standard chloroquine/primaquine treatment: once-daily oral chloroquine on day 1 (600 mg), day 2 (600 mg), and day 3 (300 mg), and oral primaquine 15 mg for 14 days from day 2.</p>
<p>The mean age (mean ± SD) of the patients was 29.8 ± 13.3 years. The admission episode was confirmed to be the first following the latest travel to malarial areas through an interview of the patient and an examination of their clinical record. The second episode was confidently classed as a true relapse because: (a) reinfection could be excluded since the relapse episode occurred when the patients were residents in or around Bangkok, a non-malaria area, without any history of travelling to any malaria endemic areas after the initial <italic>P. vivax</italic> episode; (b) the median time interval to relapse in these patients was 81 days, making it highly unlikely that this was a recrudescence, which usually occurs within 28 days after treatment [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
<p>Thirty anonymous frozen plasma samples obtained from healthy individuals resident in non-endemic areas were used as controls. These donors had no history of malaria and denied travelling to any endemic area during the 2 years preceding blood collection.</p>
<p>This study was approved by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University (Approval Number: MUTM 2013-034-01).</p>
</sec>
<sec id="Sec4">
<title>DNA template preparation</title>
<p>
<italic>Plasmodium vivax</italic> genomic DNA was extracted from 200 µL of frozen-packed red cells using the commercially available DNA Blood kit (MACHEREY–NAGEL, Germany). The final volume of the DNA template was 100 µL, thus each 1 µL corresponds to the DNA present in 2 µL of whole blood. Confirmation of microscopic diagnosis examination was achieved by a multiplex real-time PCR assay using both genus- and species-specific primers [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
</sec>
<sec id="Sec5">
<title>Genotyping of <italic>Pvmsp1</italic>F3 and <italic>Pvcsp</italic> genes</title>
<p>Polymorphic fragments of two genes: F3 fragment of the <italic>P. vivax</italic> merozoite surface protein 1 (<italic>Pvmsp1</italic>F3) and the central repeat domain of the <italic>P. vivax</italic> circumsporozoite protein (<italic>Pvcsp</italic>) were amplified by nested-PCR assay as previously described [<xref ref-type="bibr" rid="CR20">20</xref>]. The PCR products were purified using the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany) and sequenced by AIT Biotech, Singapore. The sequences were aligned and analysed using Sequencher™ software version 5.3 (Gene Codes Corporation, Ann Arbor, USA).</p>
</sec>
<sec id="Sec6">
<title>Microsatellite analysis</title>
<p>Four microsatellite (MS) markers (MS3.502, MS3.27, MS6, and MS8) were amplified using semi-nested PCR amplification as previously described [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. The length variation of labelled PCR products was measured in comparison to internal size standards (GeneScan 500 LIZ; Applied Biosystems) on an ABI Genetic Analyzer (Macogen Inc., South Korea). Allele lengths and peak heights were analysed by using PeakScanner software (Applied Biosystems). Multiple alleles were called when there were multiple peaks per locus and where the height of these minor peaks reached one-third or more (&gt;33%) of the predominant allele peak height.</p>
</sec>
<sec id="Sec7">
<title>Detection of anti-<italic>Plasmodium vivax</italic> IgG and IgG subclasses antibody</title>
<p>The anti-<italic>P. vivax</italic> IgG, IgG1, IgG2, IgG3, and IgG4 antibodies levels in the plasma samples were determined by the enzyme-linked immunosorbent assay as previously described [<xref ref-type="bibr" rid="CR23">23</xref>] with some modification using crude <italic>P. vivax</italic> blood-stage antigens. The optical density (OD) was measured at a wavelength of 450 nm by an ELISA plate Reader (Tecan Sunrise™, Austria) with Magellan™ data analysis software version 7.1 (Tecan, Austria). Plasma from normal healthy individuals was used as controls.</p>
</sec>
<sec id="Sec8">
<title>Plasma cytokine quantification</title>
<p>The plasma pro- and anti- inflammatory cytokines were quantified by human cytometric bead array (CBA) kits (BD Biosciences Pharmingen, San Jose, CA, USA) for IL-1β (interleukin-1 beta), IL-6, IL-8, IL-10, IL-12p70 and TNF (tumour necrosis factor), and by CBA Flex Set system (BD Biosciences Pharmingen, San Jose, CA, USA) for IL-2, IL-4, IL-5, IL-13, IL-17A and IFN-γ (interferon gamma). Standard curves for each cytokine were generated by using the reference cytokine concentrations supplied with the kits. All standards and plasma samples were acquired on Accuri™ C6 Plus personal flow cytometer (BD Biosciences). Data analysis was performed using the FCAP Array software version 3.0.1 (BD/Softflow, Pécs, Hungary) and the values were expressed in pg/mL.</p>
</sec>
<sec id="Sec9">
<title><italic>CYP2D6</italic> genotyping and phenotyping</title>
<p>The single-nucleotide polymorphisms (SNPs) in the human gene encoding the cytochrome P450 2D6 (<italic>CYP2D6</italic>) were determined using the Luminex xTAG CYP2D6 Kit v3 (Luminex Corporation). The assay identifies the following alleles: normal function *1, *2, *35; decreased function *9, *10, *17, *29, *41; no enzymatic function *3, *4, *5, *6, *7, *8, *11, *15, and duplications. The CYP2D6 metaboliser phenotypes were assigned according to the rule-base system of Luminex xTAG CYP2D6 Kit v3 [<xref ref-type="bibr" rid="CR24">24</xref>]. The patients were classified as (1) poor metabolisers (PM) if they harboured two null (non-functional) alleles; (2) intermediate metabolisers (IM) if they harboured two decreased function alleles, or a null allele with a decreased function allele; (3) extensive metabolisers (EM) if they harboured two functional alleles, or a functional allele with either a decreased function allele or a null allele; (4) ultra-rapid metabolizer (UM) if they harboured duplication of functional alleles.</p>
</sec>
<sec id="Sec10">
<title>Statistical analyses</title>
<p>Statistical analyses were performed using SPSS 15.0 software (SPSS Inc, Chicago, IL, USA) and Prism v.5 (GraphPad Software Inc, San Diego, CA, USA). Dimension variables were compared using Wilcoxon signed rank test for dependent data and Mann–Whitney <italic>U</italic> test for independent data. The <italic>P</italic> value of &lt;0.05 was considered as statistically significant.</p>
</sec>
</sec>
<sec id="Sec11">
<title>Results</title>
<sec id="Sec12">
<title>Homologous <italic>versus</italic> heterologous relapses</title>
<p>Genotyping based on the <italic>Pvmsp1</italic>F3 and <italic>Pvcsp</italic> was successfully achieved for the parasites in all twelve paired admission and relapse samples (Table <xref ref-type="table" rid="Tab1">1</xref>). Six distinct allelic variants (designated as “<italic>a</italic>” to “<italic>f</italic>”) were observed for <italic>Pvmsp1</italic>F3, and 13 distinct allelic variants were observed for <italic>Pvcsp</italic>: nine of the VK210 type designated as “<italic>a”</italic> to <italic>“i</italic>”, and four genotypes of the VK247 type designated as “<italic>j”</italic> to <italic>“m</italic>”. The sequences of the allelic variants are presented in Additional file <xref ref-type="media" rid="MOESM1">1</xref>. The parasites in the admission and relapse samples were also successfully genotyped using four microsatellite (MS) markers: MS3.27, MS3.502, MS6 and MS8 (Table <xref ref-type="table" rid="Tab1">1</xref>). The number of distinct allelic variants for these microsatellite markers ranged from 6 to 17. Mixed genotype infections were observed in one or both samples from seven of the patients, with a maximum of two distinct haplotypes detected in a given sample (Table <xref ref-type="table" rid="Tab1">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Genotypes of the <italic>P. vivax</italic> populations in admission and relapse episodes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Patient/age (days)<sup>a</sup>
</th><th align="left" rowspan="2">Date of sample collection (D/M/Y)</th><th align="left" rowspan="2">
<italic>Msp1</italic>F3</th><th align="left" rowspan="2">
<italic>Csp</italic>
</th><th align="left" colspan="4">Microsatellite</th></tr><tr><th align="left">MS3.27</th><th align="left">MS3.502</th><th align="left">MS 6</th><th align="left">MS 8</th></tr></thead><tbody><tr><td align="left">P1/47</td><td align="left">AS (12/3/2012)</td><td align="left">
<italic>a</italic>
</td><td align="left">VK247 <italic>j</italic>
</td><td align="left">110.7</td><td align="char" char=".">150.7</td><td align="left">252.3</td><td align="left">243.7</td></tr><tr><td align="left">(106)</td><td align="left">RS (25/6/2012)</td><td align="left">
<italic>a</italic>
</td><td align="left">VK247 <italic>j</italic>
</td><td align="left">110.7</td><td align="char" char=".">150.6</td><td align="left">252.3</td><td align="left">243.7</td></tr><tr><td align="left">P2/56</td><td align="left">AS (12/3/2012)</td><td align="left">
<italic>a</italic>
</td><td align="left">VK247 <italic>j</italic>
</td><td align="left">110.7</td><td align="char" char=".">150.7</td><td align="left">252.2</td><td align="left">243.7</td></tr><tr><td align="left">(120)</td><td align="left">RS (09/7/2012)</td><td align="left">
<italic>a</italic>
</td><td align="left">VK247 <italic>j</italic>
</td><td align="left">110.7</td><td align="char" char=".">150.6</td><td align="left">252.3</td><td align="left">243.7</td></tr><tr><td align="left">P3/50</td><td align="left">AS (12/3/2012)</td><td align="left">
<italic>a</italic>
</td><td align="left">VK247 <italic>j</italic>
</td><td align="left">110.7</td><td align="char" char=".">150.7</td><td align="left">252.3</td><td align="left">243.7</td></tr><tr><td align="left">(106)</td><td align="left">RS (25/6/2012)</td><td align="left">
<italic>a</italic>
</td><td align="left">VK247 <italic>j</italic>
</td><td align="left">110.6</td><td align="char" char=".">150.6</td><td align="left">252.3</td><td align="left">243.7</td></tr><tr><td align="left">P4/18</td><td align="left">AS (23/4/2012)</td><td align="left">
<italic>a</italic>
</td><td align="left">VK247 <italic>j</italic>
</td><td align="left">110.7</td><td align="char" char=".">150.6</td><td align="left">252.3</td><td align="left">243.7</td></tr><tr><td align="left">(44)</td><td align="left">RS (05/6/2012)</td><td align="left">
<italic>a</italic>
</td><td align="left">VK247 <italic>j</italic>
</td><td align="left">110.8</td><td align="char" char=".">150.7</td><td align="left">252.3</td><td align="left">243.8</td></tr><tr><td align="left">P5/20</td><td align="left">AS (22/5/2012)</td><td align="left">
<bold><italic>a</italic></bold>
</td><td align="left">
<bold>VK247</bold> <bold><italic>k</italic></bold>
</td><td align="left">
<bold>95.5</bold>
</td><td align="char" char=".">
<bold>150.6</bold>
</td><td align="left">252.3</td><td align="left">
<bold>311.0</bold> <bold>+</bold> <bold>314.0</bold>
</td></tr><tr><td align="left">(38)</td><td align="left">RS (28/6/2012)</td><td align="left">
<bold><italic>b</italic></bold>
</td><td align="left">
<bold>VK210</bold>
<bold><italic>a</italic></bold>
</td><td align="left">
<bold>125.9</bold>
</td><td align="char" char=".">
<bold>190.9</bold>
</td><td align="left">252.2</td><td align="left">
<bold>304.8</bold> <bold>+</bold> <bold>307.8</bold>
</td></tr><tr><td align="left">P6/22</td><td align="left">AS (02/7/2012)</td><td align="left">
<italic>c</italic>
</td><td align="left">VK210 b</td><td align="left">103.1</td><td align="char" char=".">158.8</td><td align="left">240.4</td><td align="left">311.1 + 314.1</td></tr><tr><td align="left">(120)</td><td align="left">RS (29/10/2012)</td><td align="left">
<italic>c</italic>
</td><td align="left">VK210 b</td><td align="left">103.2</td><td align="char" char=".">158.8</td><td align="left">240.3</td><td align="left">311.1 + 314.2</td></tr><tr><td align="left">P7/22</td><td align="left">AS (16/7/2012)</td><td align="left">
<italic>a</italic>
</td><td align="left">VK210 <italic>c</italic>
</td><td align="left">129.8</td><td align="char" char=".">166.8</td><td align="left">252.1</td><td align="left">223.8</td></tr><tr><td align="left">(92)</td><td align="left">RS (15/10/2012)</td><td align="left">
<italic>a</italic>
</td><td align="left">VK210 <italic>c</italic>
</td><td align="left">129.7</td><td align="char" char=".">166.9</td><td align="left">252.2</td><td align="left">223.9</td></tr><tr><td align="left">P8/31</td><td align="left">AS (07/2/2013)</td><td align="left">
<italic>a</italic>
</td><td align="left">
<bold>VK210</bold>
<bold><italic>d</italic></bold> + VK247 <italic>l</italic>
</td><td align="left">
<bold>118.2</bold>
</td><td align="char" char=".">
<bold>158.8</bold>
</td><td align="left">
<bold>246.1</bold>
</td><td align="left">
<bold>249.5</bold>
</td></tr><tr><td align="left">(67)</td><td align="left">RS (13/4/2013)</td><td align="left">
<italic>a</italic>
</td><td align="left">VK247 <italic>l</italic>
</td><td align="left">
<bold>185.9</bold>
</td><td align="char" char=".">
<bold>150.7</bold>
</td><td align="left">
<bold>240.3</bold>
</td><td align="left">
<bold>284.3</bold> <bold>+</bold> <bold>287.3</bold>
</td></tr><tr><td align="left">P9/22</td><td align="left">AS (07/8/2013)</td><td align="left">
<italic>d</italic>
</td><td align="left">VK210 <italic>e</italic>
</td><td align="left">146.3</td><td align="char" char=".">141.7</td><td align="left">240.4</td><td align="left">272.7 + 275.5</td></tr><tr><td align="left">(68)</td><td align="left">RS (13/10/2013)</td><td align="left">
<italic>d</italic>
</td><td align="left">VK210 <italic>e</italic>
</td><td align="left">146.4</td><td align="char" char=".">141.7</td><td align="left">240.3</td><td align="left">272.7 + 275.6</td></tr><tr><td align="left">P10/22</td><td align="left">AS (18/5/2013)</td><td align="left">
<italic>a</italic> + <bold><italic>e</italic></bold>
</td><td align="left">
<bold>VK210</bold>
<bold><italic>f</italic></bold>
</td><td align="left">133.8</td><td align="char" char=".">133.1</td><td align="left">243.2 + <bold>246.3</bold>
</td><td align="left">
<bold>287.1</bold> <bold>+</bold> <bold>289.9</bold>
</td></tr><tr><td align="left">(153)</td><td align="left">AS (17/10/2013)</td><td align="left">
<italic>a</italic>
</td><td align="left">
<bold>VK210</bold> <bold><italic>g</italic></bold>
</td><td align="left">133.7</td><td align="char" char=".">133.1</td><td align="left">243.16</td><td align="left">
<bold>218.2</bold>
</td></tr><tr><td align="left">P11/21</td><td align="left">AS (11/9/2013)</td><td align="left">
<italic>a</italic>
</td><td align="left">
<bold>VK210</bold> <bold><italic>h</italic></bold> + VK247 <italic>m</italic>
</td><td align="left">118.2</td><td align="char" char=".">141.7</td><td align="left">
<bold>246.2</bold>
</td><td align="left">229.5</td></tr><tr><td align="left">(40)</td><td align="left">RS (20/10/2013)</td><td align="left">
<italic>a</italic>
</td><td align="left">
<bold>VK210 </bold>
<bold><italic>i</italic></bold> + VK247 <italic>m</italic>
</td><td align="left">
<bold>110.6</bold> + 118.2</td><td align="char" char=".">141.7</td><td align="left">
<bold>240.3</bold>
</td><td align="left">229.5 + <bold>246.7</bold>
</td></tr><tr><td align="left">P12/27</td><td align="left">AS (23/10/2013)</td><td align="left">
<italic>f</italic>
</td><td align="left">VK210 <italic>b</italic>
</td><td align="left">150.6</td><td align="char" char=".">190.9</td><td align="left">261.2</td><td align="left">278.5 + 281.4</td></tr><tr><td align="left">(69)</td><td align="left">RS (30/12/2013)</td><td align="left">
<italic>f</italic>
</td><td align="left">VK210 <italic>b</italic>
</td><td align="left">150.6</td><td align="char" char=".">191.0</td><td align="left">261.2</td><td align="left">278.4 + 281.4</td></tr></tbody></table><table-wrap-foot><p>Relapse episodes were classified as heterologous when a new allelic variant was observed in this episode for at least one of the markers</p><p>
<italic>AS</italic> admission sample, <italic>RS</italic> relapse sample. Allelic variants that differ between the paired samples from each patient are presented in bold</p><p>
<sup>a</sup>The number of days between the initial admission and the relapse episode is presented in parenthesis below each patient number</p></table-wrap-foot></table-wrap>
</p>
<p>The genotyping data allowed classifying the relapse episodes as homologous or as heterologous, i.e. with genetically similar or distinct parasite populations in the paired samples, respectively. For eight patients (P1, P2, P3, P4, P6, P7, P9 and P12) the relapses were homologous, while for the other four they were clearly heterologous (Table <xref ref-type="table" rid="Tab1">1</xref>).</p>
<p>Median parasitaemia at first presentation was quite similar for the patients who then had a heterologous relapse (median and interquartile range: 349.3, 94.9–536.5 parasites/µL) as compared to those who went on to have a homologous relapse (346.5, 68.5–806.3 parasites/µL). On the other hand, the median parasitaemia at presentation of the relapse episode was higher in those with heterologous relapse (316.3, 52.1–612.3 parasites/µL) as compared to those with a homologous relapse (119.8, 50.4–190.8 parasites/µL) (Fig. <xref ref-type="fig" rid="Fig1">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Parasitaemia in admission and relapse episodes of patients with homologous and heterologous relapse. Each <italic>line</italic> represents data from one patient. Parasite numbers per microliter of blood were determined by counting the number of parasites per 200 white blood cells (WBCs) in thick films and assuming an average of 8000 WBC/µL of blood to calculate the parasitaemia (P/µL of blood)</p></caption><graphic id="MO1" xlink:href="12936_2017_1877_Fig1_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec13">
<title><italic>CYP2D6</italic> genotyping of the patients</title>
<p>The twelve patients recruited in this study had received primaquine in addition to chloroquine as treatment for the initial admission episode. Their relapse episodes could therefore be considered as hypnozoicidal treatment failures. Given that adherence to treatment was observed, failure could be due to reduced susceptibility to 8-aminoquinolines or an inability of the patients to metabolise primaquine to its active form. Recent studies showed that cytochrome P450 2D6 (CYP2D6) is implicated in the metabolism of primaquine [<xref ref-type="bibr" rid="CR25">25</xref>]. CYP2D6 is a genetically and phenotypically highly polymorphic drug-metabolizing enzyme involved in the biotransformation of numerous drugs [<xref ref-type="bibr" rid="CR26">26</xref>]. Indeed, two cases where primaquine failure was associated to carriage of a particular CYP2D6 haplotype have been recorded [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p>
<p>The CYP2D6 genotypes and the predicted metaboliser phenotypes were obtained for the patients recruited in this study (Table <xref ref-type="table" rid="Tab2">2</xref>). Eight of the patients were classed as extensive metabolisers (EM) while the remaining four were predicted to be intermediate metabolisers (IM), and their proportion in those who had a homologous relapse (3 IM/5 EM) was similar to that in those who experienced a heterologous relapse (Table <xref ref-type="table" rid="Tab2">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<italic>CYP2D6</italic> genotypes and predicted phenotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Relapse</th><th align="left">Patient</th><th align="left">Drug treatment</th><th align="left">Genotype</th><th align="left">Predicted phenotype</th></tr></thead><tbody><tr><td align="left" rowspan="8">Homologous</td><td align="left">P1</td><td align="left">C/P</td><td align="left">
<italic>*5/*10</italic>
</td><td align="left">IM</td></tr><tr><td align="left">P2</td><td align="left">C/P</td><td align="left">
<italic>*10/*10</italic>
</td><td align="left">IM</td></tr><tr><td align="left">P3</td><td align="left">C/P</td><td align="left">
<italic>*1/*41</italic>
</td><td align="left">EM</td></tr><tr><td align="left">P4</td><td align="left">C/P</td><td align="left">
<italic>*2/*10</italic>
</td><td align="left">EM</td></tr><tr><td align="left">P6</td><td align="left">C/P</td><td align="left">
<italic>*1/*1</italic>
</td><td align="left">EM</td></tr><tr><td align="left">P7</td><td align="left">C/P</td><td align="left">
<italic>*10/*10</italic>
</td><td align="left">IM</td></tr><tr><td align="left">P9</td><td align="left">C/P</td><td align="left">
<italic>*1/*10</italic>
</td><td align="left">EM</td></tr><tr><td align="left">P12</td><td align="left">C/P</td><td align="left">
<italic>*1/*10</italic>
</td><td align="left">EM</td></tr><tr><td align="left" rowspan="4">Heterologous</td><td align="left">P5</td><td align="left">C/P</td><td align="left">
<italic>*2/*10</italic>
</td><td align="left">EM</td></tr><tr><td align="left">P8</td><td align="left">C/P</td><td align="left">
<italic>*1/*10</italic>
</td><td align="left">EM</td></tr><tr><td align="left">P10</td><td align="left">C/P</td><td align="left">
<italic>*10/*41</italic>
</td><td align="left">IM</td></tr><tr><td align="left">P11</td><td align="left">C/P</td><td align="left">
<italic>*1/*2</italic>
</td><td align="left">EM</td></tr></tbody></table><table-wrap-foot><p>
<italic>C/P</italic> chloroquine/primaquine, <italic>IM</italic> intermediate metabolisers, <italic>EM</italic> extensive metabolisers</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec14">
<title>Analysis of immune responses</title>
<p>Anti-<italic>P. vivax</italic> antibody levels (IgG, IgG1, IgG2, IgG3 and IgG4) were measured in the plasma samples collected from the patients on for the initial and the relapse episodes (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). As expected the median levels (median and interquartile range) of the specific IgG, IgG1, IgG2, IgG3 and IgG4 antibodies in both episodes were significantly higher than those in normal controls (<italic>P</italic> &lt; 0.05) for all the patients. Significant differences in total IgG, IgG1, IgG2, IgG3 and IgG4 levels in paired admission and relapse episodes were not observed. This was also the case when considering samples from patients with homologous as compared to heterologous relapses, except for IgG3 where the median levels observed in the paired samples tended to be higher in patients who experienced a heterologous relapse (Fig. <xref ref-type="fig" rid="Fig2">2</xref>c).<fig id="Fig2"><label>Fig. 2</label><caption><p>Levels of <italic>Plasmodium vivax</italic>-specific IgG subclasses in plasma collected at admission and relapse. The admission and relapse episodes are represented by <italic>white</italic> and <italic>crosshatched bars</italic>, respectively, while normal controls are indicated by a <italic>black bar</italic>. The <italic>box plots</italic> show the median (50th percentile) and 25th and 75th quartiles; <italic>error bars</italic> show the 10th and 90th percentiles. Mann–Whitney <italic>U</italic> test was used to establish a significant difference (<italic>P</italic> &lt; 0.05) between groups pairwise. Wilcoxon signed rank test was used to assess the significant differences in the specific IgG subclass levels between the admission and relapse episodes</p></caption><graphic id="MO2" xlink:href="12936_2017_1877_Fig2_HTML"></graphic></fig>
</p>
<p>At both admission and relapse episodes, the median IgG3 levels in patients with heterologous relapses (admission: 0.63, 0.51–1.64; relapse: 0.61, 0.52–1.48) were relatively higher than those with homologous relapse (admission: 0.49, 0.47–0.72; relapse: 0.48, 0.43–0.67) but these were not statistically significant (<italic>P</italic> &gt; 0.05) (Fig. <xref ref-type="fig" rid="Fig2">2</xref>c).</p>
<p>The cytokine profiles were similarly measured in the plasma samples collected from the patients prior to treatment (Fig. <xref ref-type="fig" rid="Fig3">3</xref>). As expected, the median cytokine levels (median and interquartile range) in the admission and relapse episodes were higher levels than those in normal controls. No Differences in median levels were observed for IL-2, IL-4, IL-5, IL-8, IL-12p70, IL-13, IL-17A, TNF or IFN-γ in either patient groups (Fig. <xref ref-type="fig" rid="Fig3">3</xref>). IL-6 (Fig. <xref ref-type="fig" rid="Fig3">3</xref>a) and IL-10 (Fig. <xref ref-type="fig" rid="Fig3">3</xref>b) were higher in the paired samples collected from patients with heterologous relapses as compared with those who had a homologous relapse with a significant difference for IL-6 at admission [heterologous versus homologous: 86.2, 35.4–113.3 pg/mL versus 10.7, 10.1–29.6 pg/mL (<italic>P</italic> = 0.028)], while significant differences were not seen for IL-6 at relapse [54.7, 23.8–1762.9 pg/mL versus 21.2, 6.1–187.0 pg/mL (<italic>P</italic> = 0.125)], or for IL-10 for either samples [admission: 130.6, 28.4–666.3 pg/mL versus 18.9, 13.0–58.9 pg/mL (<italic>P</italic> = 0.283); relapse: 252.5, 62.4-670.2 pg/mL versus 20.9, 6.9–1118.2 pg/mL (<italic>P</italic> = 0.283)]. IL-1β levels tended to be higher in the relapse as compared to the admission sample for both homologous [relapse versus admission: 6.3, 5.4–7.7 pg/mL versus 5.5, 4.6–5.8 pg/mL (<italic>P</italic> = 0.078)] and heterologous relapses [6.6, 5.9–7.4 pg/mL versus 6.0, 5.2–6.3 pg/mL (<italic>P</italic> = 0.375)] (Fig. <xref ref-type="fig" rid="Fig3">3</xref>c).<fig id="Fig3"><label>Fig. 3</label><caption><p>Levels of cytokines in plasma collected at admission and relapse. The admission and relapse episodes were indicated by <italic>white</italic> and <italic>crosshatched bars</italic>, respectively, while the normal control was indicated by <italic>black bar</italic>. The <italic>box plots</italic> show the median (50th percentile) and 25th and 75th quartiles; <italic>error bars</italic> show the 10th and 90th percentiles. Mann–Whitney <italic>U</italic> test was used to establish a significant difference (<italic>P</italic> &lt; 0.05) between groups pairwise. Wilcoxon signed rank test was used to assess the significant differences in cytokine and chemokine levels between the admission and relapse episodes</p></caption><graphic id="MO3" xlink:href="12936_2017_1877_Fig3_HTML"></graphic></fig>
</p>
</sec>
</sec>
<sec id="Sec15">
<title>Discussion</title>
<p>The biology of hypnozoites remains very poorly investigated; indeed the few hypnozoites consequent to an infectious bite lie dormant in the liver, an organ of a mean weight of 1.5 kg in adults, where they are not amenable to experimental in vivo investigations. Thus, insights into these dormant stages are only practicably inferred indirectly through observations of the relapses they cause. The ability of hypnozoites to survive for months and years and for a subset to activate rather randomly during this time makes this task difficult. In areas where transmission occurs, it is difficult to distinguish a true relapse episode from a recrudescence or a primary episode from a new infection during the follow-up of recruited patients. However, if the patients are treated with an efficacious schizontocidal treatment and observed in areas where transmission does not occur, one can confidently consider any renewed parasitological episodes as true relapses. The first molecular analyses of paired admission/relapse samples were carried out on samples from 6 patients who acquired the infection in various endemic countries who were treated and sampled in Canada [<xref ref-type="bibr" rid="CR4">4</xref>], and the second from 10 patients recruited in an endemic region of Brazil [<xref ref-type="bibr" rid="CR5">5</xref>]. In nearly all these cases the parasites in the paired samples were similar, but there were two exceptions (one in each study) where the parasite genotypes differed. The next molecular investigations on relapses that were conducted on a large number of patients, who had acquired their infection in Indonesia [<xref ref-type="bibr" rid="CR6">6</xref>], Thailand, Myanmar or India [<xref ref-type="bibr" rid="CR7">7</xref>], clearly demonstrated that the activation of heterologous hypnozoites could actually be quite frequent. Similar subsequent studies from diverse endemic areas confirmed that this phenomenon is indeed common.</p>
<p>Variations in the proportion of heterologous relapses are likely to alter with the levels and the duration of exposure to transmission, as this will influence the number of hypnozoites that accumulate in the liver. Of the 36 patients infected in western Thailand between 1992 and 1998 [<xref ref-type="bibr" rid="CR7">7</xref>], 28 (78%) had parasite genotypes on relapse that were not observed in the admission sample. In this current study, only four of the twelve (33%) patients recruited between 2012 and 2013 showed a heterologous relapse, a decrease that might reflect the consistent reduction in the transmission intensity of <italic>P. vivax</italic> in this area (&lt;0.5 infectious bite per person per year). It should be noted that both patients infected at the eastern border and one of the two infected at the north-eastern border showed heterologous relapses, as compared to one of the eight who acquired the infection at the western border of Thailand. Indeed, along the border areas of Thailand, it has been reported that <italic>P. vivax</italic> genetic diversity and multiplicity of infection remain high despite low malaria transmission [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The proximity to the borders of Myanmar, Laos and Cambodia (all areas where malaria endemicity is higher than in Thailand) has probably contributed to increase diversity through the extensive human migration events to and from Thailand. As the genetic diversity in the background population was high, the probability of relapses likely reflects heterologous infections. A larger number of cases would need to be investigated to ascertain whether this represents a significant difference. Nonetheless, the high genetic diversity of the parasites observed in the limited number of samples analysed here, with unequivocal mixed genotype infections in three of the patients, underlines the resilience to standard control efforts that hypnozoites confer to <italic>P. vivax</italic>.</p>
<p>It is interesting to note that patients P1–P4 had parasites of the same genotype (in both admission and relapse samples). These four patients were admitted within a short period of each other (March/April 2012), making it plausible that were infected by the same strain. The short time to relapse in one of these patients (P4, 44 days) compared to the other three (P1–P3, 106–120 days) might reflect age differences in the level of acquired immunity [<xref ref-type="bibr" rid="CR31">31</xref>] as P4 was 18 years old whereas P1–P3 were 47–46 years old. Nonetheless, large variations in the time to relapse have been observed in humans inoculated experimentally with <italic>P. vivax</italic> sporozoites [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. An earlier relapse might also be due to a febrile illness that was proposed as a potential activator of latent hypnozoites [<xref ref-type="bibr" rid="CR1">1</xref>]. It should be noted that a clinically discrete or silent relapse would have been missed because the study protocol relied on presentation with clinical symptoms during the follow-up period in order to record a relapse episode.</p>
<p>The patients presented here failed to clear the hypnozoites they were carrying despite the primaquine treatment that they had received. This failure was not related to a reduced ability to metabolise 8-aminoquinolines by cytochrome P450 as a result of CYP2D6 polymorphisms, reflecting previous observations showing similar clearance rates for intermediate and extensive metabolisers [<xref ref-type="bibr" rid="CR34">34</xref>]. This suggests that some <italic>P. vivax</italic> lines circulating in Thailand might not be fully susceptible to the standard dose of primaquine (15 mg for 14 days from day 2), which should prompt reconsideration of the suitability of this dosage; all the more urgently should emergent chloroquine-resistant parasites [<xref ref-type="bibr" rid="CR35">35</xref>] spread further. At present, there is no confirmed genetic marker for primaquine resistance/tolerance, though potential mutations in some parasite genes have been identified in the relapse populations of a single patient [<xref ref-type="bibr" rid="CR36">36</xref>]. Whether any of these mutations are indeed implicated awaits comparative analysis of <italic>P. vivax</italic> isolates that have led or not to relapse infections following primaquine administration.</p>
<p>The availability of plasma samples from the patients afforded the possibility to conduct a survey of immune responses that could then be compared between admission and relapse episodes and also between homologous and heterologous episodes. Although the overall number of patients is low, particularly in the two relapse type groups, such studies have been previously rarely carried out and the comparisons could usefully serve to indicate factors that might be worth considering in future studies with larger patient groups. The levels of the twelve pro- and anti-inflammatory cytokines were as expected elevated in all groups as compared to controls, but differences between the groups were only noted for three of these: higher levels of IL-1β in the relapse as compared to the admission episode in patients with either relapse type, and elevated IL-6 and IL-10 in the paired samples from patients with heterologous as compared to homologous relapses. The significance of these observations is as yet unclear. Investigations on the cytokines profiles in <italic>P. vivax</italic> infections have to our knowledge been confined to admission and convalescent samples (for e.g. [<xref ref-type="bibr" rid="CR37">37</xref>–<xref ref-type="bibr" rid="CR40">40</xref>]) with a single study in which recurrences within 6 months, some of which might have been relapses, were included [<xref ref-type="bibr" rid="CR12">12</xref>]. Given the pleiotropic effects of cytokines, and the diversity of epidemiological settings where the studies were based, conclusions from these studies remain speculative. Overproduction of IL-lβ is known to have deleterious effects on the liver [<xref ref-type="bibr" rid="CR41">41</xref>]. Elevated levels of this cytokine are associated with the development of hepatic dysfunction in <italic>P. vivax</italic> malaria patients [<xref ref-type="bibr" rid="CR40">40</xref>]. In this study, higher IL-1β levels in the relapse than admission episode might affect the development of the hypnozoite reservoir in the liver. Recently, it has been proposed that hypnozoites of different genotypes that have accumulated from previous inoculations could be triggered to activate by a febrile illness, leading to heterologous relapses [<xref ref-type="bibr" rid="CR1">1</xref>]. Elevated IL-6 levels are associated with high fever in <italic>P. vivax</italic> malaria patients [<xref ref-type="bibr" rid="CR39">39</xref>]. The higher IL-6 levels in heterologous as compared to homologous relapses in the current study might indicate the importance of this pyrogenic cytokine in the activation of heterologous hypnozoite. IL-10 has an important regulatory role in controlling the intensity of host immune response against the circulating parasites. Elevated IL-10 levels were shown to be correlated with hyperparasitaemia in <italic>P. vivax</italic> infected patients [<xref ref-type="bibr" rid="CR42">42</xref>]. The high production of IL-10 noted for the patients with heterologous relapses suggests that it might be a regulator of immune responses harmful to the host.</p>
<p>Levels of IgG specific to <italic>P. vivax</italic> were elevated in all groups as compared to controls, which is consistent with previous observations on antibody levels [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], and on the persistence of B cell memory responses to <italic>P. vivax</italic> blood stage antigens [<xref ref-type="bibr" rid="CR43">43</xref>]. Previous studies have suggested that B cell memory responses to blood stage antigens could be stably maintained over time in the absence of reinfection even in areas of low malaria transmission [<xref ref-type="bibr" rid="CR43">43</xref>]. The present investigation provides evidence that IgG antibody response to <italic>P. vivax</italic> was not greater in relapse compared with admission episodes even in patients with homologous relapses. This observation might be explained in three possibilities. Firstly, homologous relapses might not be associated with an enhanced immune memory-driven antibody response. It is possible that any partially effective immune response to a previous <italic>P. vivax</italic> strain might have been maximized in terms of driving elevations of antibody response [<xref ref-type="bibr" rid="CR12">12</xref>]. Secondly, lower parasitaemia in homologous compared with heterologous relapses might be associated with a lower antibody response. Finally, some genotypes present in relapse episode may have been missed or only partially characterized due to insufficient numbers of parasites carrying those genotypes. Probably, in these patients with homologous relapses, the parasites causing relapses might not be identical to those of initial <italic>P. vivax</italic> infections. <italic>P. vivax</italic>-specific IgG2 and IgG3 levels were somewhat higher than those of IgG1 and IgG4 in all groups. It is not clear whether the higher median levels of IgG3 observed in both paired samples in heterologous relapses, as compared to those from homologous relapses, are of functional significance, especially as this does not correlate with the somewhat lower parasitaemia observed in homologous as compared to heterologous relapses. However, these observations might be explained by the possibility that the presence of genetically and antigenically distinct strains of the parasites during the course of infection might derive the host to mount diverse immune response against these antigenic variants. Higher parasite density may induce higher antibody responses in patients with malaria infection. In fact, IgG3 has the high binding affinity for the Fcγ receptor on the surface of monocytes, which strongly induces phagocytosis and complement fixing [<xref ref-type="bibr" rid="CR44">44</xref>]. Recent studies determined that high IgG1 and IgG3 levels were associated with high parasite density [<xref ref-type="bibr" rid="CR45">45</xref>].</p>
</sec>
<sec id="Sec16">
<title>Conclusions</title>
<p>Insights into the biology of hypnozoites, the relapses they cause, and the immunological consequences of these persistent infections are needed to tailor control measures that would effectively reduce and then eliminate vivax malaria. The sampling strategy employed here ensures that true relapse cases are investigated, though only yielding relatively a small number of patients, particularly in areas with declining vivax prevalence. The molecular investigations on the nature of the relapses provides, nonetheless, a means to monitor the efficacy of the recommended first line treatments so as to provide early warning of failing drug dosages. Immunological investigations conducted on carefully selected patients in different endemic setting will be needed to address the specifics of acquired immunity to the <italic>P. vivax</italic> infections.</p>
</sec>
</body>
<back>
<app-group>
<app id="App1">
<sec id="Sec17">
<title>Additional file</title>
<p>
<media id="MOESM1" position="anchor" xlink:href="12936_2017_1877_MOESM1_ESM.docx"><caption><p>
<bold>Additional file 1.</bold> Sequence alignment of <italic>Pvmsp1</italic>F3 and <italic>Pvcsp</italic> genes.</p></caption></media>
</p>
</sec>
</app>
</app-group>
<fn-group>
<fn>
<p>
<bold>Electronic supplementary material</bold>
</p>
<p>The online version of this article (doi:10.1186/s12936-017-1877-x) contains supplementary material, which is available to authorized users.</p>
</fn>
</fn-group>
<ack>
<title>Authors’ contributions</title>
<p>SK designed the study; SM prepared DNA extraction, performed the genotyping, ELISA and drafted the manuscript; PG supervised the genotyping techniques; SK provided the samples from <italic>P. vivax</italic>-infected patients; JT analysed the clinical data; PC performed the cytometric bead arrays; CS performed the Luminex assay; YM gave suggestion; MI provided microsatellite primers and protocols; GS and SK supervised the work and revised the manuscript. All authors read and approved the final manuscript.</p>
<sec id="FPar1">
<title>Acknowledgements</title>
<p>We wish to thank the staff and the patients at the Clinical Malaria Research Unit, Faculty of Tropical Medicine, Mahidol University, for providing blood samples.</p>
</sec>
<sec id="FPar2">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar3">
<title>Availability of data and materials</title>
<p>All data generated or analysed during this study are included in this published article and its Additional file <xref ref-type="media" rid="MOESM1">1</xref>.</p>
</sec>
<sec id="FPar4">
<title>Ethics approval and consent to participate</title>
<p>This study using the stored specimen and data was approved by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University (Approval Number: MUTM 2013-034-01). The blood and plasma of patients were obtained anonymously and recognized only by the study code number from the previous project with written informed consent (Approval Number MUTM 2012-007-02). The forms in which permission to store and use the samples and the data for future related studies are available.</p>
</sec>
<sec id="FPar5">
<title>Funding</title>
<p>This publication was made possible through the support from the Royal Golden Jubilee Ph.D. Program (RGJ Program) of the Thailand Research Fund (Grant No. PHD/0095/2554); the Office of Higher Education Commission, Ministry of Education, Thailand, Mahidol University under the National Research Universities Initiative, and the Faculty of Tropical Medicine, Mahidol University.</p>
</sec>
<sec id="FPar6">
<title>Publisher’s Note</title>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>White</surname>
<given-names>NJ</given-names>
</name>
</person-group>
<article-title>Determinants of relapse periodicity in <italic>Plasmodium vivax</italic> malaria</article-title>
<source/>Malar J
          <year>2011</year>
<volume>10</volume>
<fpage>297</fpage>
<pub-id pub-id-type="doi">10.1186/1475-2875-10-297</pub-id>
<pub-id pub-id-type="pmid">21989376</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Battle</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Karhunen</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Bhatt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gething</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Howes</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Golding</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Geographical variation in <italic>Plasmodium vivax</italic> relapse</article-title>
<source/>Malar J
          <year>2014</year>
<volume>13</volume>
<fpage>144</fpage>
<pub-id pub-id-type="doi">10.1186/1475-2875-13-144</pub-id>
<pub-id pub-id-type="pmid">24731298</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Price</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Von Seidlein</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Valecha</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nosten</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Baird</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>White</surname>
<given-names>NJ</given-names>
</name>
</person-group>
<article-title>Global extent of chloroquine-resistant <italic>Plasmodium vivax</italic>: a systematic review and meta-analysis</article-title>
<source/>Lancet Infect Dis
          <year>2014</year>
<volume>14</volume>
<fpage>982</fpage>
<lpage>991</lpage>
<pub-id pub-id-type="doi">10.1016/S1473-3099(14)70855-2</pub-id>
<pub-id pub-id-type="pmid">25213732</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Craig</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Kain</surname>
<given-names>KC</given-names>
</name>
</person-group>
<article-title>Molecular analysis of strains of <italic>Plasmodium vivax</italic> from paired primary and relapse infections</article-title>
<source/>J Infect Dis
          <year>1996</year>
<volume>174</volume>
<fpage>373</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="doi">10.1093/infdis/174.2.373</pub-id>
<pub-id pub-id-type="pmid">8699069</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirchgatter</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Del Portillo</surname>
<given-names>HA</given-names>
</name>
</person-group>
<article-title>Molecular analysis of <italic>Plasmodium vivax</italic> relapses using the MSP1 molecule as a genetic marker</article-title>
<source/>J Infect Dis
          <year>1998</year>
<volume>177</volume>
<fpage>511</fpage>
<lpage>515</lpage>
<pub-id pub-id-type="doi">10.1086/517389</pub-id>
<pub-id pub-id-type="pmid">9466551</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Auliff</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rieckmann</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Gatton</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Relapses of <italic>Plasmodium vivax</italic> infection result from clonal hypnozoites activated at predetermined intervals</article-title>
<source/>J Infect Dis
          <year>2007</year>
<volume>195</volume>
<fpage>934</fpage>
<lpage>941</lpage>
<pub-id pub-id-type="doi">10.1086/512242</pub-id>
<pub-id pub-id-type="pmid">17330782</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imwong</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Snounou</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pukrittayakamee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tanomsing</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Nandy</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Relapses of <italic>Plasmodium vivax</italic> infection usually result from activation of heterologous hypnozoites</article-title>
<source/>J Infect Dis
          <year>2007</year>
<volume>195</volume>
<fpage>927</fpage>
<lpage>933</lpage>
<pub-id pub-id-type="doi">10.1086/512241</pub-id>
<pub-id pub-id-type="pmid">17330781</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Restrepo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Imwong</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rojas</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Carmona-Fonseca</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maestre</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>High genetic polymorphism of relapsing <italic>P. vivax</italic> isolates in northwest Colombia</article-title>
<source/>Acta Trop
          <year>2011</year>
<volume>119</volume>
<fpage>23</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1016/j.actatropica.2011.03.012</pub-id>
<pub-id pub-id-type="pmid">21497586</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKenzie</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>O’Meara</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Riley</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Strain theory of malaria: the first 50 years</article-title>
<source/>Adv Parasitol
          <year>2008</year>
<volume>66</volume>
<fpage>1</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1016/S0065-308X(08)00201-7</pub-id>
<pub-id pub-id-type="pmid">18486688</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collins</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Jeffery</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>A retrospective examination of reinfection of humans with <italic>Plasmodium vivax</italic></article-title>
<source/>Am J Trop Med Hyg
          <year>2004</year>
<volume>70</volume>
<fpage>642</fpage>
<lpage>644</lpage>
<pub-id pub-id-type="pmid">15211006</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snounou</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pérignon</surname>
<given-names>J-L</given-names>
</name>
</person-group>
<article-title>Malariotherapy—insanity at the service of malariology</article-title>
<source/>Adv Parasitol
          <year>2013</year>
<volume>81</volume>
<fpage>223</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-12-407826-0.00006-0</pub-id>
<pub-id pub-id-type="pmid">23384625</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaves</surname>
<given-names>YO</given-names>
</name>
<name>
<surname>Da Costa</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>MLM</given-names>
</name>
<name>
<surname>De Lacerda</surname>
<given-names>MVG</given-names>
</name>
<name>
<surname>Coelho-Dos-Reis</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Martins-Filho</surname>
<given-names>OA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immune response pattern in recurrent <italic>Plasmodium</italic> vivax malaria</article-title>
<source/>Malar J
          <year>2016</year>
<volume>15</volume>
<fpage>445</fpage>
<pub-id pub-id-type="doi">10.1186/s12936-016-1501-5</pub-id>
<pub-id pub-id-type="pmid">27581163</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chuquiyauri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Molina</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Brouwer</surname>
<given-names>KC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-scale protein microarray comparison of human antibody responses in <italic>Plasmodium vivax</italic> relapse and reinfection</article-title>
<source/>Am J Trop Med Hyg
          <year>2015</year>
<volume>93</volume>
<fpage>801</fpage>
<lpage>809</lpage>
<pub-id pub-id-type="doi">10.4269/ajtmh.15-0232</pub-id>
<pub-id pub-id-type="pmid">26149860</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collins</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Lunde</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Skinner</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Development of antibodies to <italic>Plasmodium vivax</italic> as measured by two different serologic techniques</article-title>
<source/>Am J Trop Med Hyg
          <year>1975</year>
<volume>24</volume>
<fpage>412</fpage>
<lpage>416</lpage>
<pub-id pub-id-type="doi">10.4269/ajtmh.1975.24.412</pub-id>
<pub-id pub-id-type="pmid">1098492</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khusmith</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tharavanij</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bunnag</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Antigenic disparity of <italic>Plasmodium vivax</italic> causing initial symptoms and causing relapse</article-title>
<source/>Southeast Asian J Trop Med Public Health
          <year>1998</year>
<volume>29</volume>
<fpage>519</fpage>
<lpage>524</lpage>
<pub-id pub-id-type="pmid">10437949</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tobie</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Abele</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Contacos</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>Serum immunoglobulin levels in human malaria and their relationship to antibody production</article-title>
<source/>J Immunol
          <year>1966</year>
<volume>97</volume>
<fpage>498</fpage>
<lpage>505</lpage>
<pub-id pub-id-type="pmid">4163253</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Llanos-Cuentas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lacerda</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Rueangweerayut</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Krudsood</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Kochar</surname>
<given-names>SK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tafenoquine plus chloroquine for the treatment and relapse prevention of <italic>Plasmodium vivax</italic> malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study</article-title>
<source/>Lancet
          <year>2014</year>
<volume>383</volume>
<fpage>1049</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(13)62568-4</pub-id>
<pub-id pub-id-type="pmid">24360369</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baird</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>Chloroquine resistance in <italic>Plasmodium vivax</italic></article-title>
<source/>Antimicrob Agents Chemother
          <year>2004</year>
<volume>48</volume>
<fpage>4075</fpage>
<lpage>4083</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.48.11.4075-4083.2004</pub-id>
<pub-id pub-id-type="pmid">15504824</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamau</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tolbert</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Kortepeter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pratt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nyakoe</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Muringo</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Development of a highly sensitive genus-specific quantitative reverse transcriptase real-time PCR assay for detection and quantitation of <italic>Plasmodium</italic> by amplifying RNA and DNA of the 18S rRNA genes</article-title>
<source/>J Clin Microbiol
          <year>2011</year>
<volume>49</volume>
<fpage>2946</fpage>
<lpage>2953</lpage>
<pub-id pub-id-type="doi">10.1128/JCM.00276-11</pub-id>
<pub-id pub-id-type="pmid">21653767</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maneerattanasak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gosi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Krudsood</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tongshoob</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lanteri</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Snounou</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic diversity among <italic>Plasmodium vivax</italic> isolates along the Thai–Myanmar border of Thailand</article-title>
<source/>Malar J
          <year>2016</year>
<volume>15</volume>
<fpage>75</fpage>
<pub-id pub-id-type="doi">10.1186/s12936-016-1136-6</pub-id>
<pub-id pub-id-type="pmid">26858120</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imwong</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boel</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Pagornrat</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pimanpanarak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McGready</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>NPJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The first <italic>Plasmodium vivax</italic> relapses of life are usually genetically homologous</article-title>
<source/>J Infect Dis
          <year>2012</year>
<volume>205</volume>
<fpage>680</fpage>
<lpage>683</lpage>
<pub-id pub-id-type="doi">10.1093/infdis/jir806</pub-id>
<pub-id pub-id-type="pmid">22194628</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imwong</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pukrittayakamee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sudimack</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Mayxay</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Contrasting genetic structure in <italic>Plasmodium vivax</italic> populations from Asia and South America</article-title>
<source/>Int J Parasitol
          <year>2007</year>
<volume>37</volume>
<fpage>1013</fpage>
<lpage>1022</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijpara.2007.02.010</pub-id>
<pub-id pub-id-type="pmid">17442318</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tangteerawatana</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Perlmann</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Hayano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kalambaheti</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Troye-Blomberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Khusmith</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>IL4 gene polymorphism and previous malaria experiences manipulate anti-<italic>Plasmodium falciparum</italic> antibody isotype profiles in complicated and uncomplicated malaria</article-title>
<source/>Malar J
          <year>2009</year>
<volume>8</volume>
<fpage>286</fpage>
<pub-id pub-id-type="doi">10.1186/1475-2875-8-286</pub-id>
<pub-id pub-id-type="pmid">20003246</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanwong</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ngamsamut</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hongkaew</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nuntamool</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Puangpetch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chamnanphon</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels</article-title>
<source/>Drug Metab Pharmacokinet
          <year>2016</year>
<volume>31</volume>
<fpage>156</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="doi">10.1016/j.dmpk.2016.01.005</pub-id>
<pub-id pub-id-type="pmid">26944100</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pybus</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Marcsisin</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Deye</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Sousa</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The metabolism of primaquine to its active metabolite is dependent on CYP 2D6</article-title>
<source/>Malar J
          <year>2013</year>
<volume>12</volume>
<fpage>212</fpage>
<pub-id pub-id-type="doi">10.1186/1475-2875-12-212</pub-id>
<pub-id pub-id-type="pmid">23782898</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>S-F</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J-P</given-names>
</name>
<name>
<surname>Chowbay</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Polymorphism of human cytochrome P450 enzymes and its clinical impact</article-title>
<source/>Drug Metab Rev
          <year>2009</year>
<volume>41</volume>
<fpage>89</fpage>
<lpage>295</lpage>
<pub-id pub-id-type="doi">10.1080/03602530902843483</pub-id>
<pub-id pub-id-type="pmid">19514967</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennett</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Pybus</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Yadava</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tosh</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sousa</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>WF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Primaquine failure and cytochrome P-450 2D6 in <italic>Plasmodium vivax</italic> malaria</article-title>
<source/>N Engl J Med
          <year>2013</year>
<volume>369</volume>
<fpage>1381</fpage>
<lpage>1382</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMc1301936</pub-id>
<pub-id pub-id-type="pmid">24088113</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingram</surname>
<given-names>RJH</given-names>
</name>
<name>
<surname>Crenna-Darusallam</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Soebianto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Noviyanti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Baird</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of <italic>Plasmodium vivax</italic> acquired in Papua New Guinea</article-title>
<source/>Malar J
          <year>2014</year>
<volume>13</volume>
<fpage>488</fpage>
<pub-id pub-id-type="doi">10.1186/1475-2875-13-488</pub-id>
<pub-id pub-id-type="pmid">25495607</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kosaisavee</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hastings</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lek-Uthai</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>The genetic polymorphism of <italic>Plasmodium vivax</italic> genes in endemic regions of Thailand</article-title>
<source/>Asian Pac J Trop Med
          <year>2011</year>
<volume>4</volume>
<fpage>931</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="doi">10.1016/S1995-7645(11)60221-6</pub-id>
<pub-id pub-id-type="pmid">22118026</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Kharabora</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sattabongkot</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Muth</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ubalee</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title><italic>Plasmodium vivax</italic> isolates from Cambodia and Thailand show high genetic complexity and distinct patterns of <italic>P. vivax</italic> multidrug resistance gene 1 (<italic>pvmdr1</italic>) polymorphisms</article-title>
<source/>Am J Trop Med Hyg
          <year>2013</year>
<volume>88</volume>
<fpage>1116</fpage>
<lpage>1123</lpage>
<pub-id pub-id-type="doi">10.4269/ajtmh.12-0701</pub-id>
<pub-id pub-id-type="pmid">23509126</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luxemburger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Thwai</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>White</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Kyle</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Maelankirri</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The epidemiology of malaria in a Karen population on the western border of Thailand</article-title>
<source/>Trans R Soc Trop Med Hyg
          <year>1996</year>
<volume>90</volume>
<fpage>105</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1016/S0035-9203(96)90102-9</pub-id>
<pub-id pub-id-type="pmid">8761562</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coatney</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>MD</given-names>
</name>
</person-group>
<article-title>Studies in human malaria. XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of <italic>Plasmodium vivax</italic></article-title>
<source/>J Natl Malar Soc
          <year>1950</year>
<volume>9</volume>
<fpage>381</fpage>
<lpage>396</lpage>
<pub-id pub-id-type="pmid">14804098</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeffery</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Relapses with Chesson strain <italic>Plasmodium vivax</italic> following treatment with chloroquine</article-title>
<source/>Am J Trop Med Hyg
          <year>1956</year>
<volume>5</volume>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.4269/ajtmh.1956.5.1</pub-id>
<pub-id pub-id-type="pmid">13292645</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>St Jean</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Koh</surname>
<given-names>GCKW</given-names>
</name>
<name>
<surname>Duparc</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tafenoquine treatment of <italic>Plasmodium vivax</italic> malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial</article-title>
<source/>Malar J
          <year>2016</year>
<volume>15</volume>
<fpage>97</fpage>
<pub-id pub-id-type="doi">10.1186/s12936-016-1145-5</pub-id>
<pub-id pub-id-type="pmid">26888075</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rijken</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Boel</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Imwong</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leimanis</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Phyo</surname>
<given-names>Aung Pyae</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand</article-title>
<source/>Malar J
          <year>2011</year>
<volume>10</volume>
<fpage>113</fpage>
<pub-id pub-id-type="doi">10.1186/1475-2875-10-113</pub-id>
<pub-id pub-id-type="pmid">21545737</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bright</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Thamer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sandra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Joel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Giacomo</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Nicholas</surname>
<given-names>JW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria</article-title>
<source/>Emerg Infect Dis
          <year>2013</year>
<volume>19</volume>
<fpage>802</fpage>
<pub-id pub-id-type="doi">10.3201/eid1905.121852</pub-id>
<pub-id pub-id-type="pmid">23648098</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Yeom</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Huh</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>JY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum cytokine profiles in patients with <italic>Plasmodium vivax</italic> malaria: a comparison between those who presented with and without thrombocytopenia</article-title>
<source/>Ann Trop Med Parasitol
          <year>2003</year>
<volume>97</volume>
<fpage>339</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="doi">10.1179/000349803235002416</pub-id>
<pub-id pub-id-type="pmid">12831519</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodrigues-Da-Silva</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Lima-Junior</surname>
<given-names>JDC</given-names>
</name>
<name>
<surname>Antas</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Baldez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Storer</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Banic</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Oliveira-Ferreira</surname>
<given-names>JD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alterations in cytokines and haematological parameters during the acute and convalescent phases of <italic>Plasmodium falciparum</italic> and <italic>Plasmodium vivax</italic> infections</article-title>
<source/>Mem Inst Oswaldo Cruz
          <year>2014</year>
<volume>109</volume>
<fpage>154</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="doi">10.1590/0074-0276140275</pub-id>
<pub-id pub-id-type="pmid">24676654</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seoh</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>EH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum cytokine profiles in patients with <italic>Plasmodium vivax</italic> malaria: a comparison between those who presented with and without hyperpyrexia</article-title>
<source/>Am J Trop Med Hyg
          <year>2003</year>
<volume>68</volume>
<fpage>102</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="pmid">12556157</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeom</surname>
<given-names>J-S</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S-H</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>S-H</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H-K</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>S-Y</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>E-H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum cytokine profiles in patients with <italic>Plasmodium vivax</italic> malaria: a comparison between those who presented with and without hepatic dysfunction</article-title>
<source/>Trans R Soc Trop Med Hyg
          <year>2003</year>
<volume>97</volume>
<fpage>687</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.1016/S0035-9203(03)80104-9</pub-id>
<pub-id pub-id-type="pmid">16117964</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>TZ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Chern</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>LY</given-names>
</name>
</person-group>
<article-title>Free radical-triggered hepatic injury of experimental obstructive jaundice of rats involves overproduction of proinflammatory cytokines and enhanced activation of nuclear factor kappaB</article-title>
<source/>Ann Clin Lab Sci
          <year>2001</year>
<volume>31</volume>
<fpage>383</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="pmid">11688850</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<mixed-citation publication-type="other">da Costa AG, Antonelli LR, Costa PA, Pimentel JP, Garcia NP, Tarrago AM, et al. The robust and modulated biomarker network elicited by the <italic>Plasmodium vivax</italic> infection is mainly mediated by the IL-6/IL-10 axis and is associated with the parasite load. J Immunol Res. 2014:318250.</mixed-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wipasa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Suphavilai</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Okell</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Corran</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Thaikla</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-lived antibody and B Cell memory responses to the human malaria parasites, <italic>Plasmodium falciparum</italic> and <italic>Plasmodium vivax</italic></article-title>
<source/>PLoS Pathog
          <year>2010</year>
<volume>6</volume>
<fpage>e1000770</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1000770</pub-id>
<pub-id pub-id-type="pmid">20174609</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnadas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ratsimbasoa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tichit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bouchier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jahevitra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Picot</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title><italic>Plasmodium vivax</italic> resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in <italic>pvmdr1</italic> and <italic>pvcrt</italic>-<italic>o</italic> genes</article-title>
<source/>Antimicrob Agents Chemother
          <year>2008</year>
<volume>52</volume>
<fpage>4233</fpage>
<lpage>4240</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.00578-08</pub-id>
<pub-id pub-id-type="pmid">18809933</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Naturally acquired antibody responses to <italic>Plasmodium vivax</italic> and <italic>Plasmodium falciparum</italic> merozoite surface protein 1 (MSP1) C-terminal 19 kDa domains in an area of unstable malaria transmission in Southeast Asia</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<fpage>e0151900</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0151900</pub-id>
<pub-id pub-id-type="pmid">26999435</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>